The application of next-generation sequencing (NGS) significantly facilitates rapid screening for new cancer susceptibility genes, and indeed, a number of pathogenic variants in the so-called moderate- and low-penetrance genes, such as ATM, BRIP1, CHEK2, PALB2 or BARD1, have been reported to be correlated with a moderate lifetime risk for breast and/or ovarian cancer [9]. This evidence concerns the gene BRIP1 and cancer.